In December 2023 the FDA approved two gene therapies for sickle cell disease, one of them the first CRISPR-based medicine ever cleared anywhere. The disease affects around 100,000 people in the United States. More than two years later, STAT reported in February that about 60 patients worldwide had been treated across both products.

That gap is the story. It is not a story about whether the therapies work, which the trials addressed, and it is not primarily a story about price, though the list prices are 2.2 and 3.1 million dollars. It is a story about what has to exist between an approval and a patient, and it is the clearest available case study in why a validated therapy can sit almost unused.

From the Lab to the Ledger

Sickle cell disease comes from a single inherited change in the gene for adult hemoglobin, which makes red cells deform into a rigid crescent shape, block small vessels and trigger episodes of severe pain and organ damage. Both approved therapies work around that gene rather than correcting it. They edit or add instructions in the patient's own blood stem cells so those cells produce fetal hemoglobin, the form the body makes before birth, which does not sickle.

The treatment is not an injection. The patient's blood stem cells are collected over multiple sessions, shipped to a manufacturing facility, edited, grown and returned. Before the edited cells can take hold, the patient receives high-dose busulfan chemotherapy to clear space in the bone marrow. That conditioning is the part most patients find hardest: it is genuinely toxic, causes infertility in most recipients, and requires weeks in hospital.

The reported bottleneck is earlier and more mundane than any of that. Specialists at several sickle cell centers have told reporters that the limiting step is collecting enough stem cells in the first place. Sickle cell disease itself disturbs the bone marrow and the mobilization process, so a patient may go through repeated collection cycles and still not yield enough cells to manufacture a dose. A treatment that cannot start is not a treatment with a cost problem.

Bio-Pipeline Ledger

The two approved sickle cell gene therapies: commercially available and supported by pivotal trial data showing most treated patients free of pain crises. Validated, and reaching very few people so far.

Stem cell collection and mobilization in sickle cell patients: the current rate-limiting step, with centers reporting repeated collection attempts. A practical bottleneck rather than a scientific unknown, and the focus of active work.

Busulfan conditioning: necessary with current protocols and the main reason patients decline. Reduced-intensity and antibody-based conditioning approaches that avoid chemotherapy are in early clinical development.

Treatment center capacity: centers must be accredited and staffed before enrolling anyone, and around half of US states have had no accredited center. An access constraint with a clear geography.

In vivo editing approaches that would edit blood stem cells inside the body: would remove collection, manufacturing and conditioning in one step. Preclinical to very early clinical, not validated for broad use.

The Clinical Reality Check

What is genuinely true today is that a person with severe sickle cell disease has, for the first time, a one-time treatment with a reasonable prospect of ending their pain crises. That is a real and historic thing, and the trial evidence behind it is solid.

What is also true is that the pathway to receiving it runs months to a year, requires living near or relocating to an accredited center, involves chemotherapy that usually ends fertility, and may fail before it starts if enough stem cells cannot be collected. For a patient with moderate disease managed on hydroxyurea, declining is a defensible clinical decision rather than a failure of understanding, and several specialists have said as much.

The cost conversation deserves a correction that comes up repeatedly in reporting: some patients believe they would have to pay the list price themselves, and in practice insurers have generally agreed to cover these therapies. The financial barrier that matters is not the sticker, it is the months of travel, lost work and caregiving that the process demands and that no policy reimburses.

The wider lesson applies well beyond this disease. A great deal of attention in biotechnology goes to whether something works, and comparatively little to whether the delivery system around it can carry a patient from diagnosis to treatment. Collection capacity, center accreditation, conditioning tolerability and manufacturing turnaround are unglamorous, and they are currently the whole constraint. When the next wave of cell and gene therapies arrives, the useful question will not be what the trial showed. It will be how many people actually received it in the second year, which is a number worth asking for by name.